LIFE - aTyr Pharma concludes enrollment in mid-stage ATYR1923 study in COVID-19 patients

ATyr Pharma (LIFE) has completed enrollment of 32 subjects in Phase 2 clinical trial of its lead therapeutic candidate, ATYR1923 in hospitalized COVID-19 patients with severe respiratory complications who do not require mechanical ventilation.The subjects enrolled in the trial were randomized 1:1:1 to a single intravenous dose of either 1.0 or 3.0 mg/kg of ATYR1923 or placebo, with 60 days follow up post treatment.The trial is designed to evaluate the preliminary safety and efficacy of ATYR1923 as compared to placebo through the assessment of key clinical outcome measures such as fever and hypoxia as well as inflammatory biomarkers.The topline data from this trial is expected by the end of this year.Shares are up 5% PM.

For further details see:

aTyr Pharma concludes enrollment in mid-stage ATYR1923 study in COVID-19 patients